UNSPSC 51131751: Ozagrel hydrochloride

This classification denotes an enzyme inhibitor and antiplatelet agent with the molecular formula C13H12N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W222U960HS, chemically known as (2e)-3-[4-(1h-imidazol-1-ylmethyl)phenyl]-2-propenoic acid hydrochloride, but more generally known as ozagrel hydrochloride, which bears US NIH Compound Identifier 5282439. European Medicines Agency schedules ozagrel hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09581MIG.

Most nations, for tariff purposes, schedule ozagrel hydrochloride under HS 29332990. SMILES: C1CC(CCC1CN2CCNC2)/C=C/C(=O)O.CL.

UNSPSC 51131751 Ozagrel hydrochloride is a Commodity code that represents a specific pharmaceutical product, but state and local procurement activity under this code shows no relevant recent opportunities. The single recent posting tagged to this code—Sourcewell RFP #061626 for Law Enforcement Equipment—is unrelated to pharmaceutical procurement and does not reflect actual buying activity under the ozagrel hydrochloride classification. State and local health agencies, correctional departments, and hospital systems that purchase pharmaceutical supplies do not appear to be using this specific commodity code in current solicitations accessible through major cooperative purchasing vehicles or state procurement channels.

Without evidence of active state and local procurement under this code, there is insufficient basis to characterize issuing-body mix, geographic concentration, or representative opportunities in the pharmaceutical space. The mismatch between the code's nominal scope and the law enforcement equipment solicitation suggests either classification error in the source data or that this particular drug product is not currently being procured through standard state and local RFP, RFQ, or IFB channels at scale. Firms pursuing pharmaceutical supply contracts with state and local health departments, prisons, or institutional buyers should monitor higher-level pharmaceutical family codes and state health department solicitation channels rather than this narrowly defined commodity code.